Skip to Main Content

The Bulletin - Spring 2026

PDF

  • KTMC Achieves $239 Million Recovery for Investors in Celgene Securities Fraud Case

    Matthew Mustokoff, Aubrie Kent

    Following seven years of vigorous litigation, Kessler Topaz recently secured a landmark $239 million settlement in In re Celgene Corp. Securities Litigation, 2:18-cv-04772 (MEF) (JBC) (D.N.J.). The case, led by Lead Plaintiff AMF Tjänstepension AB (“AMF”), was prosecuted through every phase of...

  • KTMC Attains $78 Million Recovery for Investors in Catalent Quality Control and Accounting Fraud Case

    Joshua D'Ancona, Ryan Shelton-Benson

    After nearly three years of litigation in New Jersey federal court, on December 22, 2025, the parties in City of Warwick Ret. Sys. v. Catalent, Inc., et al., No. 3:23-01108 (ZNQ) (D.N.J.) announced a settlement of all claims for $78 million. If approved, the settlement will provide a substantial...

  • SEC Chairman Signals Intent to Curtail Shareholder Litigation

    Karissa Sauder

    During his ten months as Chairman of the United States Securities and Exchange Commission (the “SEC”), Paul Atkins has indicated that the SEC intends to reduce not only its own regulation of public companies and public enforcement of the federal securities laws, but also private shareholder...

  • Kessler Topaz Finalizing $70 Million Settlement After Check-Up of Veterinary Company Merger

    Michael McCutcheon

    Kessler Topaz is in the process of finalizing a $70 million cash settlement concerning a lawsuit brought by former stockholders of veterinary company Covetrus, Inc. (“Covetrus,” or the “Company”) in connection with the Company’s sale to private equity firms Clayton, Dubilier & Rice, LLC (“CD&R”)...

  • Court Denies Social Media Companies' Request for Summary Judgment; School District Trials Will Begin This Summer

    Daniel Dicce

    On February 9, 2026, Judge Gonzalez Rogers of the Northern District of California denied Meta, Snap, TikTok, and YouTube’s (“Defendants”) attempt to prevent the School District Plaintiffs (the “School Districts”) from proceeding to trial on their negligence and public nuisance claims in the...

  • KTMC Files Novel Antitrust Action Based on Improper Patent Listing

    Matthew Macken

    KTMC recently filed a novel antitrust action alleging that Novartis Pharmaceuticals Corporation (“Novartis”) illegally extended its monopoly for the blockbuster heart failure drug Entresto by improperly listing a patent in the FDA’s Orange Book. In this proprietary case, Plaintiff Iron Workers...